Loading organizations...
§ Private Profile · 1600 Hart St suite 1, Rahway, NJ 07065, USA
Manufacturer of electrophoresis equipment for life science research, focused on nucleic acid and protein analysis.
Key people at Amersham Pharmacia Biotech, Hoefer Business.
Amersham Pharmacia Biotech, Hoefer Business, based in San Francisco, California, manufactured and distributed electrophoresis equipment, gel scanners, and related consumables for protein and nucleic acid analysis in life science research. The division supplied specialized one-dimensional gel electrophoresis systems, software, and reagents directly to academic laboratories, drug discovery firms, and commercial biopharmaceutical manufacturing facilities worldwide. Operating under a parent corporation that generated £1.4 billion in sales and employed 9,000 people globally in 2001, the unit maintained a significant presence in the estimated $112 million United States electrophoresis market. Following its initial integration into Pharmacia Biotech, the division was subsequently sold to Harvard Bioscience for $5.3 million in 2003 before its broader parent organization was acquired by GE Healthcare. The original independent scientific enterprise was founded in 1967 by Peter Hoefer and Jacqueline Hoefer.
Key people at Amersham Pharmacia Biotech, Hoefer Business.
Amersham Pharmacia Biotech's Hoefer Business was a division specializing in scientific instruments for electrophoresis and protein separation, acquired by Pharmacia Biotech in 1995 from Hoefer Scientific Instruments in San Francisco.[1][4] It served life sciences researchers and pharmaceutical companies by providing tools essential for biomolecular analysis, addressing challenges in protein purification and separation during the genomics and biotech boom of the 1990s.[1][4] Integrated into the larger Amersham Pharmacia Biotech joint venture formed in 1997, it contributed to a powerhouse in life sciences tools with global distribution, later evolving under Amersham Biosciences until GE Healthcare's acquisition in 2004.[3][4][5]
This business unit exemplified the era's focus on enabling biotech R&D, with products distributed worldwide to support drug development, such as insulin manufacturing precursors like Sephadex.[1][4]
Hoefer Scientific Instruments originated as an independent supplier of electrophoresis equipment in San Francisco, known for customer-focused innovation in solving lab problems for protein separation.[4] In 1995, Pharmacia Biotech—a Swedish biotech firm renowned for products like Sephadex (launched 1960 for large-scale pharma separation)—acquired Hoefer to bolster its instrumentation portfolio.[1][4]
The pivotal moment came in 1997 when Amersham International's Life Sciences business (rooted in the UK's 1940s Radiochemical Centre for isotopes) merged with Pharmacia Biotech in a 55:45 joint venture, creating Amersham Pharmacia Biotech.[1][2][3][6] This fused Hoefer's instruments with Amersham's isotope and separation expertise, amid broader consolidations like Amersham's merger with Nycomed.[1][2] Early traction stemmed from Hoefer's hands-on customer support, leading to new product innovations.[4]
Amersham Pharmacia Biotech's Hoefer Business rode the 1990s biotech wave, fueled by genomics "firsts" like RIA kits and Sephadex, enabling pharma scale-up amid post-WWII isotope advancements.[2][5] Timing was ideal: privatization of Amersham in 1982 under Thatcher spurred agility, while 1997 mergers aligned with exploding demand for tools in drug discovery and protein analysis.[2][6][7]
Market forces like rising insulin and biologic needs favored it, influencing the ecosystem by standardizing separation techniques—someone used an Amersham product every other second globally.[2] It paved the way for GE Healthcare's life sciences dominance, with Piscataway and Uppsala as key hubs.[1][3]
By 2003, Hoefer's 1-D gel electrophoresis was divested to Harvard Biosciences with ongoing Amersham distribution, signaling a maturing pivot to broader platforms.[4] Acquired into GE Healthcare in 2004, its legacy endures in modern biomolecular tools, now part of a £2.5B+ division aiding drug and vaccine development.[3][5]
Looking ahead, trends like AI-driven proteomics and personalized medicine will amplify such instrumentation's role, evolving Hoefer's foundational tech within GE's global R&D. Its influence shifts from standalone innovator to embedded enabler in precision biotech, sustaining impact on pharma pipelines first sparked by early separators like Sephadex.[1][2]
